Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2024-12-06 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Beacon announces clinical data update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated 06 December 2024. It contains an announcement from Syncona Limited regarding positive clinical trial data for its portfolio company, Beacon Therapeutics. The structure, use of RNS identifiers, and the nature of the content (a brief update on clinical trial results and a reference to the full announcement being copied below) strongly indicate this is a regulatory news service release. Since it is an announcement of clinical data, it is not a full Annual Report (10-K) or a comprehensive Interim Report (IR). It is an announcement of scientific/clinical progress, which often falls under general regulatory filings or specific announcements. Given the context of RNS and the content being a press release summarizing data, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is focused on clinical milestones. Since RNS is the designated category for general regulatory announcements not covered elsewhere, and this is clearly an RNS distribution, I will classify it as RNS.
2024-12-06 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document is a formal announcement filed via RNS (RNS Number: 0355P) on December 6, 2024. The title and content explicitly state 'Transaction in Own Shares' and detail the purchase of 150,000 Ordinary Shares as part of a share buyback programme. This directly corresponds to the definition of a company buying back or selling its own shares. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS).
2024-12-06 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document is an official announcement disseminated via RNS (RNS Number : 8583O) on December 5, 2024. The title and content explicitly state 'Transaction in Own Shares' and detail the purchase of 150,000 ordinary shares by the company on December 4, 2024, including prices and the resulting change in treasury shares and total voting rights. This directly corresponds to the definition of a company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category (POS). Although it is distributed via RNS, the specific subject matter is not general regulatory news but a specific corporate action.
2024-12-05 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document is a formal announcement dated December 4, 2024, originating from 'RNS Number : 6681O' and referencing the London Stock Exchange's primary information provider. The title of the announcement is 'Transaction in Own Shares'. The content details the purchase of 600,000 ordinary shares by the company on December 3, 2024, as part of a share buyback programme, and updates the total voting rights. This directly corresponds to the definition of a company reporting the repurchase or sale of its own shares. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS).
2024-12-04 English
Transaction in Own Shares
Transaction in Own Shares Classification · 1% confidence The document explicitly states it is announcing a 'Transaction in Own Shares' as part of a 'share buyback programme'. It details the number of shares purchased, the price paid, and the resulting change in total voting rights. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). Although it is distributed via RNS, the specific content dictates the POS classification over the general RNS fallback.
2024-12-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) of the London Stock Exchange. It explicitly states the 'Total Voting Rights' as of a specific date (30 November 2024) and provides the denominator figure required by DTR 5.6.1 (Disclosure Guidance and Transparency Rules). This type of announcement, dealing with the total number of shares in issue and voting rights, is a specific regulatory disclosure. While it relates to share capital, it is not a general share issue (SHA) or a transaction in own shares (POS), but rather a mandatory periodic disclosure regarding voting rights. Since it is a regulatory announcement that doesn't fit perfectly into the other specific categories (like ER, 10-K, DIV), and it is distributed via RNS, the most appropriate classification is the general regulatory filing category, RNS, as it is a standard regulatory update.
2024-12-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.